UK considerations NHS and MHRA guidance The UK health authorities have clear positions on weight loss treatments: The NHS offers GLP-1 medications through specialist weight management services for eligible patients MHRA has approved Wegovy, Saxenda, and Mounjaro based on comprehensive safety and efficacy data No GLP-1 patch products have received MHRA approval as weight loss treatments The MHRA has issued warnings about misleading claims in weight loss supplements Cost and access in the UK The financial aspect is a significant consideration for many: NHS provision : Limited availability through specialist weight management services with strict eligibility criteria Private prescriptions : 150-300 monthly, depending on medication and provider Commercial patches : 12-70 monthly, depending on brand and quantity While patches appear less expensive, they lack evidence of effectiveness, making them poor value regardless of price
But lower hunger doesn't remove the need for nutrition structure
83,89,90,91,92 Since then, it has also been approved for other indications, such as chronic weight management, under the brand name Saxenda
Commercial Readiness: Chinas Market Prepares for a GLP-1 Boom The Chinese GLP-1 market is poised for significant expansion, with both multinational and domestic pharmaceutical companies gearing up for commercial launches
